Business Wire

CA-VELO3D

24.8.2021 15:34:09 CEST | Business Wire | Press release

Share
Velo3D Expands Team in Europe to Support Growing Demand for Industrial Metal Additive Manufacturing

As global demand for top-quality 3D-printed industrial parts continues to grow, California-based Velo3D, Inc. , a leader in advanced additive manufacturing (AM) for high-value metal parts, has announced the appointment of two new Europe-based senior executives.

Managing Director, Dr. Jose Greses , will be based between Germany and Spain while Sales Director, Xavier Fruh , will be located in France. They join Jon Porter , who was appointed earlier this year as European Business Development Director based in the U.K.

Dr. Greses holds a Ph.D. in laser welding from the University of Cambridge (U.K.) and a M.Sc. in Marine Technology from Cranfield University (U.K.). He has worked for a number of leading European manufacturing companies in laser welding and 3D-printing—most recently with GF Machining Solutions and, prior to that, for 14 years with German AM company EOS.

"Our goal is to help industries solve their engineering challenges by delivering unprecedented design freedom, part repeatability and quality in metal 3D printing," says Dr. Greses. "We're here to provide the European markets with a seamless transition to Velo3D's end-to-end manufacturing solution including its advanced support-free technology."

Xavier Fruh has a Master's degree in electrical engineering from ESIGELEC Rouen and an M.B.A. from the Strasbourg School of Management, both in France. He has years of experience in the welding industry and most recently did business development around Europe for four years with AddUp, a French group specializing in AM technology.

"I am passionate about innovation and technology," Fruh says. "I'm keen to support our customers in overcoming the limits of traditional manufacturing and to help them take advantage of everything that AM, the next generation of manufacturing engineering, has to offer."

Benny Buller , founder and CEO of Velo3D, views his company's European growth as a sign of greater awareness of the production metrics delivered by advanced 3D-printing systems. "Expanding our footprint in Europe comes in response to new demand for the very highest-achievable levels of metal AM quality that only Velo3D provides--as well as design freedom that can unleash innovation and improve competitiveness for industries such as aerospace, oil and gas, and alternative energy," he says.

In March, Velo3D announced plans to merge with JAWS Spitfire Acquisition Corporation (NYSE: SPFR ) and become a public company.

To learn more about how Velo3D empowers engineers and designers to imagine more and additively manufacture nearly anything, follow Velo3D on LinkedIn or visit velo3d.com .

About Velo3D

Velo3D, one of Fast Company’s 2021 World’s Most Innovative Companies , empowers engineers and designers to imagine more and additively manufacture nearly anything with a fully-integrated patented solution of software, hardware, and process-control featuring FlowTM print preparation software, AssureTM quality assurance software and the Sapphire® family of laser powder bed 3D printers. Velo3D additive manufacturing solutions for 3D-printing high-value metal parts allow for previously impossible geometries, so businesses can make the mission-critical parts they need without compromise. Customers include some of the world’s most visionary companies, such as Aerojet Rocketdyne, Chromalloy, Honeywell, LAM Research and Raytheon Technologies. For more information, follow Velo3D on LinkedIn or visit velo3d.com.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye